Debasis Mohapatra
Bengaluru, 20 Nov 2025
Sudeep Pharma is a leading manufacturer of mineral-based pharmaceuticals, food, nutrition, and speciality ingredients in India, including iron phosphate and encapsulated preservatives such as sorbic acid and calcium propionate.
As the company’s IPO is all set to hit the market in India, here is a snapshot of its performance.
Financial Performance:
| Particulars | FY25 | YoY Growth |
| Revenue | Rs 501.9 crore | 9.27% ↑ |
| PAT | Rs 138.6 crore | 4.13% ↑ |
| EBITDA Margin | 39.70% | 1.18% ↓ |
| PAT Margin | 27.63% | 1.37% ↓ |
| Net Debt to Equity | 0.20 | 3 basis points ↑ |
Segment Revenue contribution:
| Particulars | FY25 Revenue in absolute term | % of Total Revenue |
| Pharmaceutical, food and nutrition | Rs 330.4 crore | 65.84% |
| Specialty ingredients | Rs 171.5 crore | 34.16% |
| Particulars | Q1FY26 (April-June) Revenue in absolute term | % of Total Revenue |
| Pharmaceutical, food and nutrition | Rs 82.98 crore | 66.43% |
| Specialty ingredients | Rs 41.9 crore | 33.57% |
Geographical contribution to Revenue in FY25:
| Particulars | FY25 Revenue in absolute term | % of Total Revenue |
| India | Rs 204.4 crore | 40.73% |
| North America | Rs 116.4 crore | 23.19% |
| Asia-Pacific | Rs 71.96 crore | 14.34% |
| Europe | Rs 48.11 crore | 9.59% |
| Middle East and Africa | Rs 43.2 crore | 8.61% |
| Others | Rs 17.83 crore | 3.55% |
